We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder


Department of Health written question – answered on 27th February 2017.

Alert me about debates like this

Photo of Mary Glindon Mary Glindon Shadow Minister (Environment, Food and Rural Affairs) (Farming and Rural Communities)

To ask the Secretary of State for Health, what clinical evidence available after 2011 was considered by NHS England for inclusion in the evidence summary for Selective Internal Radiation Therapy under the Commissioning through Evaluation scheme.

Photo of David Mowat David Mowat The Parliamentary Under-Secretary of State for Health

The journal articles listed below became available after 2011 and were included in the Selective Internal Radiation Therapy evidence review undertaken by NHS England in 2013:

- Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2012 Oct 24; ePub doi: 10.1007/s00270-012-0481-2.

- Iñarrairaegui M, Pardo F, Bilbao JI et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012; 38: 594–601.

- Xie F, Zang J, Guo X et al. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2012; 138: 455‒462.

- Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma Br J Surg. 2012 Dec;99(12):1711-7.

- Hoffmann RT, Paprottka PM, Schön A et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Interv Radiol 2012; 35: 105–116.

- Shaheen M, Hassanain M, Aljiffry M et al. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB 2012; 14: 60–66.

- Memon K, Lewandowski RJ, Mulcahy MF et al. Radioembolization for neuroendocrine liver metastases: Safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83: 887–894.

- Bester L, Meteling B, Pocock N et al. Radioembolization versus standard care of hepatic metastases: Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23: 96–105.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.